losartan has been researched along with bosentan anhydrous in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (25.00) | 18.2507 |
2000's | 11 (39.29) | 29.6817 |
2010's | 10 (35.71) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Bai, R; Jiang, J; Liu, J; Wang, Q; Wei, Z; Wu, X; Xie, W; Xu, J; Yao, H | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Leskinen, H; Ruskoaho, H; Vuolteenaho, O | 1 |
Magga, J; Marttila, M; Ruskoaho, H; Vuolteenaho, O | 1 |
Charlier, AA; Donckier, JE; Heyndrickx, GR; Hodeige, DG; Ketelslegers, JM; Massart, PE; Van Mechelen, H | 1 |
Demeilliers, B; Herizi, A; Jover, B; Mimran, A | 1 |
Baylis, C; Qiu, C | 1 |
Borthayre, AB; Harrison, DG; Hink, U; Kurz, S; Münzel, T; Nickenig, G | 1 |
Bellissant, E; Durand-Castel, X; Goineau, S; Guillo, P; Pape, D | 1 |
Beresewicz, A; Maczewski, M | 1 |
Belabbas, H; Herizi, A; Jover, B; Mimran, A | 1 |
Juncos, LA; Manriquez, MC; Ortiz, MC; Romero, JC; Sanabria, E | 1 |
Gosek, K; Grzeszczak, W; Zukowska-Szczechowska, E | 1 |
Chen, Y; Tang, T; Wang, X; Zhang, J | 1 |
Capuano, V; Coulombe, A; Deroubaix, E; Ferron, L; Renaud, JF; Ruchon, Y | 1 |
Elena, JV; Grujić-Adanja, G; Jerkić, M; Jovović, D; López-Novoa, JM; Manero, MV; Marković-Lipkovski, J; Mihailović-Stanojević, N; Miloradović, Z; Nastić-Mirić, D; Prieto, MP; Rodríguez-Barbero, A; Vojvodić, SB | 1 |
Charles, CJ; Espiner, EA; Frampton, CM; Nicholls, MG; Rademaker, MT; Richards, AM | 1 |
Jerkić, M; Jovović, D; Marković-Lipkovski, J; Mihailović-Stanojević, N; Milanović, JG; Miloradović, Z; Stosić, G | 1 |
Banoglu, ZN; Dengiz, GO; Kandemir, NO; Kurcer, Z; Mungan, G; Ozacmak, VH; Turkili, B | 1 |
Bahde, R; Bandi, S; Bhargava, KK; Gupta, S; Kapoor, S; Palestro, CJ | 1 |
De Mey, JG; Janssen, B; Lemkens, P; Meens, MJ; Nelissen, J; Peters, SL; Schiffers, PM; Spijkers, LJ | 1 |
2 review(s) available for losartan and bosentan anhydrous
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Antihypertensive treatment in patients with diabetes mellitus].
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Bosentan; Diabetes Complications; Endothelins; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Losartan; Sulfonamides; Time Factors | 2002 |
1 trial(s) available for losartan and bosentan anhydrous
Article | Year |
---|---|
Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Bosentan; Cardiac Output; Cardiac Output, Low; Cardiac Pacing, Artificial; Cyclic GMP; Endothelin Receptor Antagonists; Endothelin-1; Female; Infusions, Parenteral; Losartan; Natriuretic Peptide, Brain; Renin; Sheep; Sulfonamides | 2004 |
25 other study(ies) available for losartan and bosentan anhydrous
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; CHO Cells; Cricetinae; Endothelin A Receptor Antagonists; Humans; Male; Molecular Structure; Rats; Rats, Inbred SHR; Receptors, Angiotensin; Structure-Activity Relationship; Sulfonamides | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Function, Right; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Volume; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hemodynamics; Hormones; Imidazoles; Losartan; Male; Myocardium; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptides, Cyclic; Plasma Substitutes; Pressure; Protein Precursors; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles | 1997 |
Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Losartan; Male; Myocardium; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Perfusion; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Tetrazoles | 1997 |
Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Bosentan; Disease Models, Animal; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Renovascular; Infusions, Intravenous; Losartan; Radioimmunoassay; Receptor, Endothelin A; Sulfonamides; Vascular Resistance | 1998 |
[Renal alterations in L-NAME hypertension: influence of losartan and bosentan].
Topics: Albuminuria; Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Hemodynamics; Hypertension; Kidney; Kidney Function Tests; Losartan; Male; NG-Nitroarginine Methyl Ester; Rats; Rats, Wistar; Sulfonamides | 1998 |
Endothelin and angiotensin mediate most glomerular responses to nitric oxide inhibition.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; Kidney Glomerulus; Losartan; Male; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Rats; Rats, Sprague-Dawley; Renal Circulation; Sulfonamides | 1999 |
Evidence for a causal role of the renin-angiotensin system in nitrate tolerance.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Tolerance; Endothelium, Vascular; Female; Gene Expression; Losartan; Luminescent Measurements; Male; Multienzyme Complexes; NADH, NADPH Oxidoreductases; NADPH Oxidases; Nitrates; Nitric Oxide; Nitroglycerin; Peptidyl-Dipeptidase A; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; RNA, Messenger; Sulfonamides; Superoxides; Vasoconstriction; Vasodilation; Vasodilator Agents | 1999 |
Endothelin, but not angiotensin II, contributes to the hypoxic contractile response of large isolated pulmonary arteries in the rat.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Azepines; Bosentan; Calcium; Calcium Channel Blockers; Endothelin Receptor Antagonists; Endothelins; Endothelium, Vascular; Extracellular Space; Glycopeptides; Hypoxia; In Vitro Techniques; Indoles; Lisinopril; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nicardipine; Pulmonary Artery; Rats; Rats, Wistar; Sulfonamides | 1999 |
The role of endothelin, protein kinase C and free radicals in the mechanism of the post-ischemic endothelial dysfunction in guinea-pig hearts.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Alkaloids; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Aspartic Acid Endopeptidases; Benzophenanthridines; Bosentan; Captopril; Catalase; Coronary Vessels; Endothelin-Converting Enzymes; Endothelins; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Female; Free Radicals; Glycopeptides; Guinea Pigs; Heart; Losartan; Male; Metalloendopeptidases; Muscle Proteins; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Nitroprusside; Oxidative Stress; Phenanthridines; Prazosin; Protein Kinase C; Reactive Oxygen Species; Sulfonamides; Superoxide Dismutase; Tetradecanoylphorbol Acetate; Vasodilator Agents | 2000 |
[Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan].
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Carotid Arteries; Endothelin Receptor Antagonists; Endothelins; Follow-Up Studies; Hypertension; Hypertrophy; Losartan; Male; Organ Size; Rats; Rats, Sprague-Dawley; Sulfonamides | 2000 |
Role of endothelin and isoprostanes in slow pressor responses to angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Bosentan; Endothelins; Glomerular Filtration Rate; Infusions, Intravenous; Losartan; Nitrites; Prostaglandins; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Sulfonamides | 2001 |
Effect of angiotensin II receptor antagonist and endothelin receptor antagonist on nitroglycerin tolerance in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Drug Tolerance; Endothelin Receptor Antagonists; Losartan; Male; Nitroglycerin; Rats; Rats, Wistar; Sulfonamides; Vasodilator Agents | 2001 |
Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Bosentan; Butadienes; Calcium Channels, T-Type; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; Constriction, Pathologic; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; Flavonoids; Gene Expression; Losartan; Male; Membrane Potentials; Mitogen-Activated Protein Kinase Kinases; Myocytes, Cardiac; Nickel; Nitriles; Oligopeptides; Peptides, Cyclic; Piperidines; Rats; Rats, Wistar; Receptors, Angiotensin; Receptors, Endothelin; RNA, Messenger; Signal Transduction; Sulfonamides | 2003 |
Relative roles of endothelin-1 and angiotensin II in experimental post-ischaemic acute renal failure.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Infusions, Intravenous; Kidney; Losartan; Male; Models, Animal; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides | 2004 |
Bosentan and losartan ameliorate acute renal failure associated with mild but not strong NO blockade.
Topics: Acute Kidney Injury; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Cardiac Output; Heart Rate; Infusions, Intravenous; Kidney; Losartan; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Wistar; Regional Blood Flow; Sulfonamides; Vascular Resistance | 2007 |
Role of angiotensin and endothelin in testicular ischemia reperfusion injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Bosentan; Enalapril; Endothelin Receptor Antagonists; Endothelins; Losartan; Male; Malondialdehyde; Rats; Rats, Wistar; Reperfusion Injury; Statistics, Nonparametric; Sulfonamides; Testis | 2012 |
Directly acting drugs prostacyclin or nitroglycerine and endothelin receptor blocker bosentan improve cell engraftment in rodent liver.
Topics: Animals; Bosentan; Cardiovascular Agents; Dipeptidyl Peptidase 4; Endothelin Receptor Antagonists; Epoprostenol; Hepatocytes; Lisinopril; Liver; Losartan; Nitroglycerin; Rats; Rats, Inbred F344; Sulfonamides | 2013 |
Dual NEP/ECE inhibition improves endothelial function in mesenteric resistance arteries of 32-week-old SHR.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzazepines; Bosentan; Endothelin-Converting Enzymes; Endothelium, Vascular; Enzyme Inhibitors; Hydralazine; Hypertension; Losartan; Mesenteric Arteries; Muscle Contraction; Neprilysin; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Protease Inhibitors; Rats; Rats, Inbred SHR; Sulfonamides; Vascular Resistance | 2017 |